Download Metabolic Phenotyping in Cancer Research

Factsheet Cancer Research
W
th e
to e P pro
th he vid
e
Ge not e
no ype
ty
pe
!
Metabolic Phenotyping
in Cancer Research
• Targeted & Quantitative Analysis
• Standardized & Quality Controlled
• Easy to use Kits & Services
Metabolites are direct molecular readouts of cell status that reflect a meaningful physiological phenotype.
Alterations in metabolic activity are intimately related with the cancer phenotype and its sustenance. BIOCRATES
helps researchers to further understand what is happening in cancer cells.
“Three metabolites (lyspPC a C16:0, PC ae C42:5,
PC aa C34:2) successfully differentiate breast
cancer patients from healthy controls with a sensitivity of 98.1% and a specificity of 96.0%.”
Qiu et al. Int. J. Mol. Sci., 2013, 14, 8047-8061.
Mass Spectrometry-Based Quantitative Metabolomics Revealed a Distinct Lipid Profile in Breast Cancer
Patients.
Jaeger et al. OMICS, 2011, 15.
“Metabolomic analysis elucidated several small
Metabolomic Analysis of Resveratrol-Induced Effects
molecules as markers for the response of breast
in the Human Breast Cancer Cell Lines MCF-7 and
cancer cells to resveratrol.“
MDA-MB-231
“Recent advances in analytical technologies and
statistical capabilities have provided metabolomics Berger, R.D. Metabolites 2013, 3, 552-574.
the ability to probe much further into the meta- A Review of Applications of Metabolomics in Cancer.
bolism of cancer.”
Many top-notch international cancer research facilities are already using BIOCRATES‘ metabolomics solutions, i.e.
German Cancer Research Center, The Institute of Cancer Research/GB, National Cancer Institute CRO-IRCCS/
Italy.
•
•
•
•
•
•
Biomarkers for early cancer diagnosis, better knowledge of pathological pathways of cancer
Tumor staging
Determination of treatment efficacy, drug response
Developing novel therapeutics (personalized medicine)
Metabolic characterization of tissue and plasma samples from different cancer patients
Integrate metabolomics with other ‘omics’-disciplines to identify markers (plasma) for diagnosis, therapy, and
relapse
BIOCRATES‘ easy-to-use Kits and customized Services permit precise and quality-controlled quantification of
hundreds of endogenous metabolites. We provide standardized and targeted metabolomics data which enables
researchers to compare their results across their labs and beyond.
BIOCRATES Life Sciences AG
Eduard-Bodem-Gasse 8
A-6020 Innsbruck. Austria
tel: +43 (0) 512 579 823
fax: +43 (0) 512 579 823 - 329
[email protected]
www.biocrates.com
FN220414p Landesgericht Innsbruck
Publication Cancer Research
Mass Spectrometry-Based Quantitative Metabolomics Revealed a Distinct
­Lipid Profile in Breast Cancer Patients
Qiu et al.
Int. J. Mol. Sci. 2013, 14, 8047-8061; doi:10.3390/ijms14048047
Common methods for diagnosis lack sensitivity and specificity.
Targeted Metabolomics can be used to classify breast cancer on the basis of tumor biology, to identify new prognostic and predictive markers and to discover new targets for future therapeutic interventions.
In the study from Qiu et al., the LC-MS/MS based AbsoluteIDQ® p180 Kit - (BIOCRATES Life Sciences AG,
­Austria) was used to analyze plasma samples from 55 breast cancer patients and 25 healthy controls.
With a sensitivity of 98.1% and a specificity of 96.0% breast cancer patients were ­successfully
separated from healthy controls using the BIOCRATES AbsoluteIDQ® p180 Kit.
Figure 2: Heatmap representing
the changed level
in amino acids
amongst the tissue samples
Figure 1: Scatter plot for y-values calculated from an established breast cancer versus healthy control diagnostic equation. Samples in blue represent healthy controls,
while samples in red represent breast cancer patients.
39 differentiating metabolites were identified, including significantly lower levels of lysophosphatidylcholines
and higher levels of sphingomyelins in the plasma samples obtained from breast cancer patients compared
with healthy controls. A diagnostic equation using three metabolites (lysoPC a C16:0, PC ae C42:5 and PC
aa C34:2) was established:
Metabolic Phenotyping assists in early disease diagnosis, staging and subtyping at the molecular level, reveal biological disease mechanism, and will open up the opportunity to develop individually adapted forms
of therapies.
• Common methods for diagnosis lack the sensitivity and specificity.
• Metabolomics provide clinically useful biomarkers in breast cancer, enabling a better stratification of patients
• BIOCRATES AbsoluteIDQ® p180 Kit can be used to identify breast cancer biomarkers and successfully distinguish between healthy and cancer patients.
References:
Qiu Y, Zhou B, Su M, Baxter S, Zheng X, Zhao X, Yen Y, Jia W. Mass Spectrometry-Based Quantitative Metabolomics Revealed a Distinct Lipid
Profile in Breast Cancer Patients. International Journal of Molecular Sciences. 2013; 14(4):8047-8061.
Denkert C, Bucher E, Hilvo M, Salek R, Orešic M, Griffin J, Brockmöller S, Klauschen F, Loibl S, Barupal DK, Budczies J, Iljin K, Nekljudova V, Fiehn
O. Metabolomics of human breast cancer: new approaches for tumor typing and biomarker discovery. Genome Med. 2012; 4(4):37.
Zhang AH, Sun H, Qiu S, Wang XJ. Metabolomics in noninvasive breast cancer. Clin Chim Acta. 2013; 424:3-7.
BIOCRATES Life Sciences AG
Eduard-Bodem-Gasse 8
A-6020 Innsbruck. Austria
tel: +43 (0) 512 579 823
fax: +43 (0) 512 579 823 - 329
[email protected]
www.biocrates.com
FN220414p Landesgericht Innsbruck